AL-LAD Legal status Legal status
: DE NpSG (Industrial and scientific use only)
UK: Class A Illegal in Denmark, Sweden and Switzerland Identifiers
(6aR,9R)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide CAS Number PubChem CID ChemSpider UNII ChEMBL CompTox Dashboard ( EPA) Chemical and physical data Formula C 22 H 27 N 3 O Molar mass 349.4713 g/mol g·mol −1 3D model ( JSmol)
(what is this?) (verify)
AL-LAD, also known as 6-, is a allyl-6- nor-LSD psychedelic drug and an analog of lysergic acid diethylamide (LSD). It is described by  Alexander Shulgin in the book ( TiHKAL Tryptamines i Have Known And Loved). It is synthesized starting from nor-LSD as a precursor, using allyl bromide as a reactant.
Effects in humans
AL-LAD on blotter paper
While AL-LAD has subtly different effects than LSD, and appears to be slightly shorter lasting, their potencies are similar;
 an active dose of AL-LAD is reported to be between 50 and 150  micrograms. AL-LAD has a known but short and highly uncommon history of recreational human use, which originated in Ireland and the UK, but spread internationally.
AL-LAD does not cause a color change with the
Marquis, Mecke or Mandelin reagents, but does cause the  Ehrlich's reagent to turn purple because of the presence of the indole moiety in its structure.
AL-LAD is not scheduled by the
United Nations' Convention on Psychotropic Substances.
AL-LAD is illegal in Denmark.
AL-LAD is possibly illegal in Latvia. Although it isn't specifically scheduled, it may be controlled as an LSD structural analog due to an amendment made on June 1, 2015.
AL-LAD is illegal in Romania. It is not included directly in the list of controlled substances, but it is included in
an analogue act
The Riksdag added AL-LAD to Narcotic Drugs Punishments Act under swedish schedule I ( "substances, plant materials and fungi which normally do not have medical use" ) as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 6-allyl-6-nor-LSD, AL-LAD, and 6-allyl-N,N-dietyl-9,10-didehydroergolin-8-karboxamid.
AL-LAD is illegal in Switzerland.
AL-LAD is illegal in the UK. On June 10, 2014 the UK
Advisory Council on the Misuse of Drugs (ACMD) recommended that AL-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of  The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
AL-LAD is not
scheduled as a controlled substance at the federal level in the United States, but AL-LAD could legally be considered an  analog of LSD, in which case, sales or possession with intent for human consumption could be prosecuted under the Federal Analogue Act.
Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. (January 2017). "6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 9 (1): 38–50. doi: 10.1002/dta.1985. PMC . 5411264 PMID 27265891.
Schifano F, Orsolini L, Papanti D, Corkery J (June 2016). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. Current Topics in Behavioral Neurosciences. 32. Springer International Publishing. pp. 351–380. doi: 10.1007/7854_2016_15. ISBN . 978-3-319-52442-9 OCLC 643052237. PMID 27272067.
Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. doi: 10.1021/jm00147a022. PMID 4032428.
Shulgin, Alexander (1997). . Berkeley, California: Transform Press. p. 392. TiHKAL: The Continuation ISBN . 978-0-9630096-9-2 Archived from the original on 2015-11-18.
Ecstasydata. "EcstasyData.org - AL-LAD (Not sold as ecstasy)". Archived from the original on 2013-12-26 . Retrieved . 2013-12-25
simone.rupprich. "Conventions". www.unodc.org. Archived from the original on 12 January 2018 . Retrieved . 4 May 2018
"Lists of euphoriant substances". The Danish Medicines Agency. September 2015. Archived from the original on 2016-06-09.
"Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem". LIKUMI.LV. Archived from the original on 4 May 2018 . Retrieved . 4 May 2018
"Gemensamma författningssamlingen avseende hälso- och sjukvård, socialtjänst, läkemedel, folkhälsa m.m." [Joint constitutional collection on health care, social services, pharmaceuticals, public health, etc.] (PDF). Lakemedelsverket (in Swedish). Archived (PDF) from the original on 2017-10-31 . Retrieved . 2017-04-21
"Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat. Archived from the original on 2016-01-23.
ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Archived (PDF) from the original on 6 October 2014 . Retrieved . 10 June 2014
"PART 1308 - Section 1308.11 Schedule I". www.deadiversion.usdoj.gov. Archived from the original on 27 August 2009 . Retrieved . 4 May 2018
"Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary". www.erowid.org. Archived from the original on 17 April 2018 . Retrieved . 4 May 2018
Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–9. doi: 10.1007/BF02245940. PMID 7568626.
Niwaguchi T, Nakahara Y, Ishii H (May 1976). "[Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds]". Yakugaku Zasshi. 96 (5): 673–8. doi: 10.1248/yakushi1947.96.5_673. PMID 987200. > Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994). "Lysergamides revisited" (PDF). Hallucinogens: An Update. NIDA Research Monograph. 146. United States Department of Health and Human Services. pp. 52–73. PMID 8742794. Archived from the original (PDF) on 2015-07-23.